FGFR2 inhibition could suppress spermatogenesis. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full text component. If you have the appropriate ...
New research supports the use of a circulating tumor cell (CTC) blood test, rather than the standard PSA biomarker diagnostic, to predict a patient's odds of surviving prostate cancer. A team at the ...
STIC CTC trial data published this November 2023 in the Journal of Clinical Oncology (JCO) demonstrate that CTC-guided treatment decision confers superior survival benefits in a subgroup of patients ...
Bologna, Italy and Huntingdon Valley, Pa. -- Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the ...
Washington, DC – Researchers at Georgetown Lombardi Comprehensive Cancer Center say the number of circulating tumor cells (CTCs) in the blood is a "powerful predictor" to help physicians more reliably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results